Status: Recruiting
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.
Participants needed: 133
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: The Netherlands Cancer InstituteUpdated: Mar 5, 2026Locations: 1
Eligibility criteria
Signed written informed consent [+11]
Signs of distant metastases on imaging and physical examination [+17]